Abstract
Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 261-267 |
| Number of pages | 7 |
| Journal | Diabetes and Metabolism |
| Volume | 22 |
| Issue number | 4 |
| State | Published - Jul 1996 |
| Externally published | Yes |
Fingerprint
Keywords
- growth hormone
- insulin resistance
- insulin sensitivity
- insulin-like growth factor-I
- Type 2 diabetes mellitus
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology
- Endocrinology, Diabetes and Metabolism
Cite this
IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance. / Froesch, E. R.; Bianda, T.; Hussain, Mehboob.
In: Diabetes and Metabolism, Vol. 22, No. 4, 07.1996, p. 261-267.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance
AU - Froesch, E. R.
AU - Bianda, T.
AU - Hussain, Mehboob
PY - 1996/7
Y1 - 1996/7
N2 - Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.
AB - Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.
KW - growth hormone
KW - insulin resistance
KW - insulin sensitivity
KW - insulin-like growth factor-I
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=0030015606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030015606&partnerID=8YFLogxK
M3 - Article
C2 - 8767173
AN - SCOPUS:0030015606
VL - 22
SP - 261
EP - 267
JO - Diabetes and Metabolism
JF - Diabetes and Metabolism
SN - 1262-3636
IS - 4
ER -